Diagnostic tools company Prescient Medicine Holdings Inc disclosed on Tuesday the completion of the acquisition of AutoGenomics Inc for an undisclosed amount.
Based in the US, AutoGenomics Inc is a molecular diagnostics company that has developed and commercialised the INFINITI platform, a 510(k) exempt, automated, microarray-based multiplexing diagnostic system for personalised medicine, pain management, cardiovascular health, mental health, women's health, oncology, infectious diseases and genetic disorders.
Following the acquisition of AutoGenomics, Prescient Medicine will now advance the development and commercialisation of the INFINITI Neural Response Panel, a novel diagnostic test for the identification of patients who may be at risk for opioid use disorder (OUD), through the US FDA's de Novo premarket submission.
In conjunction with the acquisition, Prescient Medicine will market the INFINITI Neural Response Panel as LifeKit Predict to provide physicians with objective information to help assess the risk of developing an addiction to oral opioids.
The acquisition provides Prescient Medicine with access to the entire INFINITI product portfolio including the suite of INFINITI analyzers and a menu of over 65 molecular diagnostic tests across critical disease indications, which will complement Prescient Medicine's LifeKit product line of diagnostics.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML